AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
Homerun Resources Inc. Announces Closing of Initial Tranche of Convertible Security Financing with the Lind Partners Under Engagements with Benchmark/StoneX
Premier American Uranium Identifies Multiple Mineralized Uranium Trends in Ongoing Drilling at Kaycee, Wyoming
